"The stock market is a wonderfully efficient mechanism for transferring wealth from the impatient to the patient."
I am also frustrated with the lack of transparency. However, I firmly believe good things are on the horizon. Not one thing has pointed otherwise. Of course we were not happy with the way Missling chose not to highlight the monotherapy. I believe he did not want to pump or set unrealistic expectations.
Other than that, he has not taken one misstep in the way he las lead this company to where we are now. I challenge anyone to point out 1.
A little copying and pasting for you. In less than two months, Anavex has updated us on 3 significant events and participated in 2 conferences. They definitely have not been sitting on their asses. This looks like a company that is diligently working towards greatness. And soon, 9 and 12 month data release.
October 5th Anavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
September 28th Anavex Compound to be Tested in Biogen Neurological Protection Model anavex.com/
September 22nd Anavex Life Sciences’ Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease anavex.com/
September 20th Anavex to Present at Ladenburg Thalmann 2016 Healthcare Conference anavex.com/
September 14th Anavex to Participate in Mizuho Therapeutics Conference anavex.com/
News 
Market Data 
Discover 
